期刊
EUROPEAN JOURNAL OF NEUROLOGY
卷 28, 期 8, 页码 2533-2542出版社
WILEY
DOI: 10.1111/ene.14845
关键词
clinical score; disability; multiple sclerosis; prognosis
资金
- Biogen
- Genzyme
- Novartis
- Teva
- Italian MS Society (Associazione Italiana Sclerosi Multipla)
- Bayer
- Teva Pharmaceutical Industries Ltd
- Bracco
- Merck-Serono
- Stendhal
- OLEA Medical
- Roche
- Sanofi-Aventis
- Almirall
- Celgene
- Merck Serono
- Bayer-Schering
- CSL Behring
- Allergan
- Hoffmann-La Roche
- Sanofi
The study aimed to develop and validate a scoring system combining baseline prognostic factors and 1-year variables of treatment response to predict the long-term risk of disability accumulation in patients with RRMS. The RoAD score showed to be a useful tool in predicting the risk of reaching a disability milestone and optimizing treatment strategy for RRMS patients.
Background and purpose Both baseline prognostic factors and short-term predictors of treatment response can influence the long-term risk of disability accumulation in patients with relapsing-remitting multiple sclerosis (RRMS). The objective was to develop and validate a scoring system combining baseline prognostic factors and 1-year variables of treatment response into a single numeric score predicting the long-term risk of disability. Methods We analysed two independent datasets of patients with RRMS who started interferon beta or glatiramer acetate, had an Expanded Disability Status Scale (EDSS) score <4.0 at treatment start and were followed for at least 10 years. The first dataset ('training set') included patients attending three MS centres in Italy and served as a framework to create the so-called RoAD score (Risk of Ambulatory Disability). The second ('validation set') included a cohort of patients followed in Barcelona, Spain, to explore the performance of the RoAD score in predicting the risk of reaching an EDSS score >= 6.0. Results The RoAD score (ranging from 0 to 8) derived from the training set (n = 1225), was based on demographic (age), clinical baseline prognostic factors (disease duration, EDSS) and 1-year predictors of treatment response (number of relapses, presence of gadolinium enhancement and new T2 lesions). The best cut-off score for discriminating patients at higher risk of reaching the disability milestone was >= 4. When applied to the validation set (n = 296), patients with a RoAD score >= 4 had an approximately 4-fold increased risk for reaching the disability milestone (p < 0.001). Discussion The RoAD score is proposed as an useful tool to predict individual prognosis and optimize treatment strategy of patients with RRMS.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据